Chronic inflammatory demyelinating polyneuropathy (CIDP), is a symmetrical sensorymotor neuropathy and is considered to be the chronic variety of the Guillain-Barre syndrome (GBS), an acute immune-mediated polyneuropathy.' CIDP and GBS differ mainly in onset, course and prognosis. Patients with GBS generally have progressive weakness of less than four weeks.2 In contrast, most patients with CIDP have progressive weakness during a longer period of time, often exceeding two months. It was recently suggested that the term "subacute" inflammatory demyelinating polyneuropathy should be reserved for those patients with a progressive course of four to eight weeks. 3 According to recent criteria, the minimal duration of progression in CIDP patients should be at least two months. 4 Patients with CIDP may respond to treatment with corticosteroids and to plasma exchange (PE), as demonstrated in randomised clinical trials.56 The chronic course of CIDP in principle offers the possibility of using various kinds of treatment or different dose schedules in single patients. However, the course of CIDP is not completely predictable as these patients can either have spontaneous relapses or a rapid spontaneous clinical improvement which has been observed in some patients even after a course of severe progressive weakness during several months,7 and indicates the need for properly designed controlled studies.
IVIg treatment in CIDP Long term treatment with corticosteroids can have serious side-effects.8 PE is a time consuming procedure, needing specialised equipment and good vascular access. Complications of PE in patients with CIDP are generally not severe. In the early 1980s, when the results of the corticosteroid and PE trials in patients with CIDP were not available, fresh-frozen plasma (FFP) and later on IVIg was administered to 17 16 In this cross-over study all the patients deteriorated after discontinuation of regular IVIg treatment. Thereafter, the patients were randomised to IVIg (0-4 g/kg) or placebo (albumin) for five consecutive days of treatment. All the patients responded after IVIg and none responded after placebo treatment. Improvement after IVIg was always observed within one week after the start of treatment. The time-lapse from the end of trial treatment to deterioration was significantly longer after treatment with IVIg (mean 6-4 weeks) than after placebo treatment (mean [1] [2] [3] 
weeks).
In a retrospective study involving 52 patients with CIDP, it was found that 32 antibodies present in serum from patients that have recovered from GBS can inhibit anti-NBL antibody activity in serum from patients with CIDP or with active GBS.27-29 These inhibitory antibodies which develop during recovery from GBS are also present in IVIg. Affinity chromatography revealed that these anti-idiotypic antibodies constitute less than 1% of the total IgG antibodies present in IVIg."0 It is, however, not proven that the various antibodies, including anti-NBL antibodies (that are present in GBS and in CIDP patients) have a direct pathogenic role in the process of disease. Whether a large pool of donors is essential for improvement from GBS or CIDP is questionable since we have observed that improvement from CIDP can also occur after intermittent infusions of fresh frozen plasma (FFP) obtained from a limited number (20-28) of donors.9 Although the mechanism of action of IVIg in patients with GBS or CIDP is far from clarified, there are arguments obtained from in vitro studies that V region-dependent interaction may play a role in the regulation of GBS and CIDP.
Conclusion
Patients with CIDP can improve after IVIg treatment. The proportion of patients that improve after IVIg is difficult to establish and seems to be dependent on the selection of patients. Further studies should focus on prognostic criteria in relation to improvement after IVIg. Studies comparing the effect of IVIg with PE or steroids are eagerly awaited. These studies, however, should not only look for the initial clinical significant improvement, but should also study the necessity of maintenance treatment. Since most patients with a CIDP need treatment for a long period of time, cost-benefit studies need to focus not only on the initial phase of treatment but also on the effects of long-term treatment including the potential side-effects of steroid treatment. We have such a study in progress now. Studies on small numbers of CIDP patients with a monoclonal gammopathy suggest that these patients may respond after IVIg as well. However, controlled studies are urgently 
